Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMROSE: Rilematovir in High-Risk Adult Outpatients With RSV Infection
jRCT2031210527Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Rilematovir arm with Placebo arm (2 arms). Primary endpoint: Time to Resolution of RSV Lower Respiratory Tract Disease Symptoms (RiiQ Symptom Scale). Started Apr 2022; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031210527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210527.